Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba A. Bagegni, X. Cynthia|Breast Cancer Research|2017Cited by 70